Evaluation of cross-protection of African swine fever vaccine ASFV-G-ΔI177L between ASFV biotypes
Background/Objectives: Vaccine development for the prevention of ASF has been very challenging due to the extensive genetic and largely unknown antigenic diversity. Inactivated vaccines, using different inactivation methods and a variety of adjuvants, have been consistently inefficacious. Historical...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Journal Article |
| Lenguaje: | Inglés |
| Publicado: |
MDPI
2025
|
| Materias: | |
| Acceso en línea: | https://hdl.handle.net/10568/176106 |
Ejemplares similares: Evaluation of cross-protection of African swine fever vaccine ASFV-G-ΔI177L between ASFV biotypes
- ASFV genome sequencing
- Accelerating African Swine Fever Virus (ASFV) vaccine development via CRISPR-Cas9 and synthetic biology technologies
- A mathematical model that simulates control options for African swine fever virus (ASFV)
- Application of Novel Delivery systems for ASFV antigens
- African swine fever virus (ASFV): Biology, genomics and genotypes circulating in sub-Saharan Africa
- Genotyping of African swine fever virus (ASFV) isolates associated with disease outbreaks in Uganda in 2007